Webster Brian Daniel sold $443K of KMTS

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

Kestra Medical Technologies (KMTS) reported a 60% revenue increase to $31.0M in Q1 2027, with gross margin rising to 56.5%. The company raised fiscal 2027 revenue guidance to $141M. Gross profit nearly doubled, but operating losses widened to $37.7M due to higher expenses. The company's cash position decreased slightly, with $244.7M remaining.

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.

Kestra Medical Technologies (KMTS) reported Q1 FY2027 revenue of $31.0M, beating estimates and raising FY2027 guidance to $141M. Gross margin improved to 56.5%, but EPS missed by 66.7%. Management expects mid-70% gross margin in 2–3 years. Next catalysts include late-stage R&D updates and Q2 earnings. Analysts maintain a Strong Buy rating with $30 price targets.

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue of $31.0M, up 60% YoY, and raised full-year guidance to $141M. Gross margin increased to 56.5%, driven by volume leverage and cost improvements. The company invested heavily in R&D and commercial expansion, resulting in a GAAP net loss of $44.1M. Management highlighted market share gains and expanded payer coverage for non-ischemic patients.

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.